BTN1A1, a member of the butyrophilin group , represents an intriguing therapeutic target for multiple immune disorders. The ICT-01-N297A antibody , specifically designed to recognize BTN1A1, offers a novel https://www.targetmol.com/compound/ict_01_n297a